Archynetys Live news trend intelligence
▲ Peaking Health

NUS researchers find drug that turns off ‘master switch’ in aggressive breast cancer

Researchers at the National University of Singapore have identified a drug that targets a molecular switch in aggressive breast cancer.

By · Published August 24, 2026 at 14:42 UTC · Updated August 24, 2026 at 16:24 UTC

6sources
6articles
4velocity
+31%since first seen
14h agofirst detected

Evidence dossier

Intelligence passport

57/100 Publishable
6distinct sources shown
15velocity measurements
1language editions checked
Unsupported statements were removed before publicationbrief evidence status

Measured timeline

  1. Detected The first matching coverage entered the Archynetys cluster.
  2. Latest coverage observed Most recent article currently attached to this story cluster.
  3. Peak measured velocity The recorded velocity reached 4.
  4. Evidence threshold reached The story had enough independent coverage for an explanatory brief.

Source diversity sample: FemTech World · Drug Target Review · Inside Precision Medicine · Medical Xpress · The Straits Times · The Star.

How this dossier is built: methodology · AI policy · corrections.

The story so far

The switch, identified as DP103, is linked to treatment resistance and metastasis in triple-negative breast cancer. The drug shows promise in turning off this switch, potentially offering a new treatment avenue for one of the deadliest forms of breast cancer. The discovery follows extensive research into the mechanisms driving triple-negative breast cancer.

The Straits Times and The Star both name the drug, DP103. The Straits Times also notes the drug's promise in treating triple-negative breast cancer. The next steps involve further clinical trials to validate the drug's efficacy and safety.

The research team aims to advance the drug through clinical development, with the goal of bringing it to patients as quickly as possible.

Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 1h ago.

The reporting (6)

The obvious questions

What is the name of the drug?

The drug is named DP103.

What type of breast cancer does the drug target?

The drug targets triple-negative breast cancer.

What is the significance of the molecular switch DP103?

The molecular switch DP103 is linked to treatment resistance and metastasis in triple-negative breast cancer.

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Topics

breast cancer triple-negative breast cancer DP103 National University of Singapore cancer research

Related trends

Open prediction lab

Can you beat the machine?

Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.

Make a prediction →